IBRN news

iShares Neuroscience and Healthcare · Biotechnology · Genomics & Biotech Innovation

Stories about this fund's companies, ranked by fund weight and recency. Times are local.

Seeking Alpha · 28 Oct 2026, 20:02 UTC
Biogen anticipates $250M of run rate synergies by end of 2027 as it raises 2026 non-GAAP EPS to $12.20-$13 (NASDAQ:BIIB) | Seeking Alpha
4.2% of IBRN
Seeking Alpha · 28 Oct 2026, 20:00 UTC
Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript | Seeking Alpha
4.2% of IBRN
Seeking Alpha · 28 Oct 2026, 19:01 UTC
Biogen Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:BIIB) 2026-10-28 | Seeking Alpha
4.2% of IBRN
Investing.com · 28 Oct 2026, 13:52 UTC
Earnings call transcript: Biogen beats Q3 2026 estimates as growth portfolio expands By Investing.com
4.2% of IBRN
Where to buy IBRN
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
The Wall Street Journal · 28 Oct 2026, 11:09 UTC
Biogen Swings to Loss, Logs Higher Sales
4.2% of IBRN
Seeking Alpha · 28 Oct 2026, 11:04 UTC
Biogen posts Q3 beat on multiple sclerosis drugs (BIIB:NASDAQ) | Seeking Alpha
4.2% of IBRN
Where to buy IBRN
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Bloomberg Business · 28 Oct 2026, 10:15 UTC
Biogen Sales Top Estimates With Help From Newly Acquired Drugs
4.2% of IBRN
Investing.com · 28 Oct 2026, 10:14 UTC
Biogen beats Q3 estimates, raises guidance floor on growth By Investing.com
4.2% of IBRN
Investor's Business Daily · 28 Oct 2026, 10:10 UTC
Biogen Makes A Solid Return 'To Growth' -- What To Know
4.2% of IBRN
Reuters · 28 Oct 2026, 10:09 UTC
Biogen beats third-quarter results on strength in rare disease drugs
4.2% of IBRN
The Manila times · 27 Oct 2026, 20:21 UTC
Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
4.9% of IBRN
Investing.com · 28 Oct 2026, 20:12 UTC
Mizuho raises AxoGen stock price target to $65 on growth outlook By Investing.com
2.3% of IBRN
Investing.com · 27 Oct 2026, 09:44 UTC
Why is Dianthus Therapeutics stock gaining today? By Investing.com
5.3% of IBRN
Investing.com · 28 Oct 2026, 13:12 UTC
AxoGen Q3 2026 slides: revenue surges 26%, breast growth accelerates By Investing.com
2.3% of IBRN
Investing.com · 28 Oct 2026, 13:02 UTC
Earnings call transcript: AxoGen beats Q3 2026 estimates and lifts outlook By Investing.com
2.3% of IBRN
Seeking Alpha · 27 Oct 2026, 17:57 UTC
AxoGen Q3 2026 Earnings Preview (NASDAQ:AXGN) | Seeking Alpha
2.3% of IBRN
Market Screener · 26 Oct 2026, 16:36 UTC
Neurocrine Biosciences, Inc. Presents New Analysis Establishing Benchmark For Clinically Meaningful Change In Overall Health Reported By Patients With Tardive Dyskinesia Treated With INGREZZA
4.1% of IBRN
Investing.com · 26 Oct 2026, 14:32 UTC
Axsome Therapeutics stock may move 8.6% on earnings report By Investing.com
3.8% of IBRN
Markets Insider · 26 Oct 2026, 03:20 UTC
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Boston Scientific (BSX)
3.9% of IBRN
wallstreet:online · 26 Oct 2026, 20:35 UTC
Sarepta Therapeutics to Present at Upcoming Investor Conferences
1.6% of IBRN

IBRN news

Where to buy IBRN

Where to buy IBRN